Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 9/20 | 0.46 |
| ▸ | JAK3 | P52333 | 9/20 | 0.46 |
| ▸ | AURKA | O14965 | 4/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.46 |
| ▸ | PLK4 | O00444 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 2/20 | 0.46 |
| ▸ | CSF1R | P07333 | 2/20 | 0.46 |
| ▸ | RET | P07949 | 2/20 | 0.46 |
| ▸ | KIT | P10721 | 2/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.46 |
| ▸ | TYK2 | P29597 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10312222 | 0.92 | HRH4 (0.50) | NTRK1HRH4JAK2JAK3AURKA | |
| SCHEMBL10312095 | 0.90 | HRH4 (0.61) | NTRK1HRH4JAK2JAK3AURKA | |
| SCHEMBL10312086 | 0.90 | HRH4 (0.48) | NTRK1HRH4JAK2JAK3AURKA | |
| SCHEMBL10312145 | 0.90 | AURKA (0.56) | NTRK1KDM4EJAK2JAK3AURKA | |
| SCHEMBL10312099 | 0.90 | HRH4 (0.46) | NTRK1HRH4KDM4EJAK2JAK3 | |
| SCHEMBL10312104 | 0.89 | NTRK1 (0.54) | NTRK1HRH4JAK2JAK3AURKA | |
| SCHEMBL10312075 | 0.89 | USP2 (0.50) | NTRK1HRH4JAK2JAK3AURKA | |
| SCHEMBL10312221 | 0.89 | HRH4 (0.48) | NTRK1HRH4JAK2JAK3AURKA | |
| SCHEMBL10312175 | 0.87 | HRH4 (0.57) | NTRK1HRH4JAK2JAK3AURKA | |
| SCHEMBL10312157 | 0.87 | IGF1R (0.47) | HRH4KDM4EPLK4PAK4PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | STK25, STK35, SGK2 | NTRK1 482/4885HRH4 2393/4885KDM4E 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.